NCT05673460View on ClinicalTrials.gov

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

April 28, 2025

Study Completion Date

September 3, 2025

Conditions
Mature B-cell Neoplasms
Interventions
DRUG

Nemtabrutinib

Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg

Trial Locations (7)

2778577

National Cancer Center Hospital East ( Site 0002), Kashiwa

466-8560

Nagoya University Hospital ( Site 0003), Nagoya

589-8511

Kindai University Hospital ( Site 0006), Sayama

260-8717

Chiba Cancer Center ( Site 0005), Chiba

812-8582

Kyushu University Hospital ( Site 0008), Fukuoka

700-8558

Okayama University Hospital ( Site 0007), Okayama

990-9585

Yamagata University Hospital ( Site 0001), Yamagata

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY